CLINICAL TRIALS PROFILE FOR NEPTAZANE

All Clinical Trials for NEPTAZANE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01587027 ↗	Safety Evaluation of Aminophylline and Methazolamide	Completed	Defense Advanced Research Projects Agency	Phase 1	2011-12-01	This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.
NCT01587027 ↗	Safety Evaluation of Aminophylline and Methazolamide	Completed	University of Colorado, Denver	Phase 1	2011-12-01	This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.
NCT01587027 ↗	Safety Evaluation of Aminophylline and Methazolamide	Completed	Poudre Valley Health System	Phase 1	2011-12-01	This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.
NCT01702025 ↗	Rapid Acclimatization to Hypoxia at Altitude	Completed	Defense Advanced Research Projects Agency	Phase 1/Phase 2	2012-06-01	In low oxygen environments, such as altitude, some adults may become ill and suffer from acute mountain sickness. Further, all adults will find that exercising becomes much more difficult when compared with exercise at lower altitudes (e.g. sea-level). The purpose of this investigation is to study the effects of two drugs that may help people adjust to high-altitude quickly, prevent them from becoming ill and improve their exercise performance. The drugs are Methazolamide and Aminophylline.

Clinical Trial Conditions for NEPTAZANE

Condition Name

Condition Name for NEPTAZANE
Intervention	Trials
Glaucoma	1
Mountain Sickness	1
Physiological Function in Low Oxygen Environment	1

Condition MeSH

Condition MeSH for NEPTAZANE
Intervention	Trials
Hypoxia	1
Anoxia	1
Altitude Sickness	1
Glaucoma	1

Clinical Trial Locations for NEPTAZANE

Trials by Country

Trials by Country for NEPTAZANE
Location	Trials
United States	3

Trials by US State

Trials by US State for NEPTAZANE
Location	Trials
Colorado	2
Florida	1

Clinical Trial Progress for NEPTAZANE

Clinical Trial Phase

Clinical Trial Phase for NEPTAZANE
Clinical Trial Phase	Trials
Phase 3	1
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for NEPTAZANE
Clinical Trial Phase	Trials
Completed	2
Active, not recruiting	1

Clinical Trial Sponsors for NEPTAZANE

Sponsor Name

Sponsor Name for NEPTAZANE
Sponsor	Trials
Defense Advanced Research Projects Agency	2
University of Colorado, Denver	2
Poudre Valley Health System	1

Sponsor Type

Sponsor Type for NEPTAZANE
Sponsor	Trials
Other	5
U.S. Fed	2
NIH	1

NEPTAZANE Market Analysis and Financial Projection

Last updated: May 8, 2026

Clinical Trials Update, Market Analysis and Projection for NEPTAZANE

No actionable, verifiable information is available in the provided context to support a complete clinical trials update, market analysis, or forward market projection for the drug NEPTAZANE.

If NEPTAZANE refers to a specific proprietary product, the clinical program, regulatory status, trial identifiers (NCT/EudraCT), sponsor, endpoints, timelines, and market inputs (incidence, target population, dosing, pricing, channel, geographies) are required to produce an investment-grade projection. Those inputs are not present here, so any attempt to populate them would be non-factual.

What is known about NEPTAZANE’s clinical development?

No trial-level facts (study identifiers, phases, patient numbers, outcomes, interim reads, recruitment status, or safety signals) are provided.

What is NEPTAZANE’s commercial positioning and addressable market?

No commercial facts are provided (indication, mechanism, target population, standard of care, competitor products, pricing, payor mix, geography, or adoption assumptions).

What is the market projection for NEPTAZANE?

No projection inputs are provided (launch year, label scope, probability-weighted uptake, penetration curves, pricing assumptions, discounting, and forecast horizon).

Key Takeaways

• NEPTAZANE-specific clinical, regulatory, and market inputs are not present in the provided context.
• A complete clinical trials update, market analysis, and forecast cannot be produced without verifiable NEPTAZANE facts.

FAQs

1. What clinical trial updates can be issued for NEPTAZANE?
   None can be issued from the provided context because no trial identifiers or outcomes are provided.

2. Which geographies should be included in NEPTAZANE market projections?
   No geographies are specified in the provided context.

3. What indication should NEPTAZANE’s market analysis focus on?
   No indication is provided in the provided context.

4. What baseline comparators should be used for NEPTAZANE adoption modeling?
   No standard-of-care or competitor set is provided in the provided context.

5. What pricing and reimbursement assumptions apply to NEPTAZANE?
   No pricing or reimbursement assumptions are provided in the provided context.